The hemophagocytic syndrome/macrophage activation syndrome: A final common pathway of a cytokine storm

Israel Medical Association Journal

Volumn 11, Issue 10, 2009, Pages 633-634

  Szyper Kravitz, Martine ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Ebstein barr virus; Hemophagocytic syndrome; Infections; Macrophage activation syndrome

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CYCLOSPORIN A; CYTOKINE; DEXAMETHASONE; ETANERCEPT; ETOPOSIDE; FERRITIN; FIBRINOGEN; GAMMA INTERFERON; GRANZYME; IMMUNOGLOBULIN; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 25; INTERLEUKIN 6; LACTATE DEHYDROGENASE; LIPOPROTEIN LIPASE; METHYLPREDNISOLONE; PERFORIN; RITUXIMAB; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

AUTOSOMAL RECESSIVE DISORDER; COMORBIDITY; CYTOKINE RELEASE; CYTOPENIA; CYTOTOXIC T LYMPHOCYTE; EDITORIAL; FEVER; GENE MUTATION; HEMOPHAGOCYTIC SYNDROME; HEPATOSPLENOMEGALY; HUMAN; HYPERTRIGLYCERIDEMIA; HYPOFIBRINOGENEMIA; IMMUNOSTIMULATION; JUVENILE RHEUMATOID ARTHRITIS; LYMPHADENOPATHY; MACROPHAGE ACTIVATION; MACROPHAGE ACTIVATION SYNDROME; MORTALITY; MULTIPLE ORGAN FAILURE; NATURAL KILLER CELL; PANCYTOPENIA; PROGNOSIS; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; STEM CELL TRANSPLANTATION; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; SYSTEMIC VASCULITIS; T LYMPHOCYTE ACTIVATION;

ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; DIAGNOSIS, DIFFERENTIAL; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MACROPHAGE ACTIVATION SYNDROME; MALE; RECEPTORS, TUMOR NECROSIS FACTOR; YOUNG ADULT;

EID: 70350635660     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (10)

1. Fukaya S, Yasuda S, Hashimoto T, et al. Clinical features of haemophagocytic syndrome in patients with systemic autoimmune diseases: analysis of 30 cases. Rheumatology 2008; 47: 1686-1691
2. Dhote R, Simon J, Papo T, et al. Reactive hemophagocytic syndrome in adult systemic diseases: report of 26 cases and literature review. Arthritis Rheum 2003; 49: 633-639 (Pubitemid 37296468)
3. Komp DM, McNamara J, Buckley P. Elevated soluble interleukin-2 receptor in childhood hemophagocytic histiocytic syndromes. Blood 1989; 73: 2128-2132 (Pubitemid 19179544)
4. Imashuku S, Hibi S, Sako M, et al. Soluble interleukin-2 receptor: a useful prognostic factor for patients with hemophagocytic lymphohistiocytosis. Blood 1995; 86: 4706-4707
5. Schneider EM, Lorenz I, Muller-Rosenberger M, Steinbach G, Kron M, Janka-Schaub GE. Hemophagocytic lymphohistiocytosis is associated with deficiencies of cellular cytolysis but normal expression of transcripts relevant to killer-cell-induced apoptosis. Blood 2002; 100: 2891-2898
6. Janka GE. Hemophagocytic syndromes. Blood Rev 2007; 21: 245-253
7. Elazary AS, Wolf DG, Amir G, et al. Severe Epstein-Barr virus-associated hemophagocytic syndrome in six adults. J Clin Virol 2007; 40: 156-159 (Pubitemid 47419424)
8. Imashuku S, Kuriyama K, Teramura T, et al. Requirement for etoposide in the treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. J Clin Oncol 2001; 19: 2665-2673 (Pubitemid 32441371)
9. Aikawa NE, Freire Carvalho J, Bonfá E, Lotito APN, SilvasCAA. Macrophage activation syndrome associated with etanercept in a child with systemic onset juvenile idiopathic arthritis. IMAJ Isr Med Assoc J 2009; 11:635-636
10. Behrens EM. Macrophage activation syndrome in rheumatic disease: what is the role of the antigen presenting cell? Autoimmun Rev 2008; 7: 305-308